htmlType 12 diabetes When blood sugar cannot meet the standards under the control of exercise and diet, anti-glycemic drugs should be used in time to treat it.
1. Sulfonylureas secrete insulin. Suitable for type 2 diabetes that is not obese.
Glibenclamide | has strong effects, low price, and can easily cause hypoglycemia. The elderly, liver and kidney function are not good, use |
with caution | |
glipizine , zit | reduces platelet adhesion, can delay complications |
glibizine, zit sluggish control-release tablets | effect Gentle, more suitable for the elderly, mild renal insufficiency can be used |
gliquine | metabolites have bile excretion, so those with kidney function impairment can use ( renal deficiency ) |
glimepiride | lowering of glycemic effects strong |
Adverse reactions of this type of medicine: hypoglycemia, weight gain, skin allergies, and digestive tract reactions.
2, glinide insulin secretion.
Reglinide , Naglinide. It is mainly used to control after meals of . Adverse reactions and contraindications are the same as sulfonylureas.
3. Biguanidines increase insulin sensitivity and take first-line medication.
is widely used to increase the sensitivity of peripheral tissues to insulin and increase the uptake and utilization of glucose . Do not increase weight, improve blood lipids and and reduce platelet aggregation, which can delay and improve complications.
4, glitone insulin sensitizer
rosiglitazone, pioglitazone. Common adverse reactions are weight gain and edema, which is suitable for type 2 obese people.
5, a-glucosidase inhibitor delays the absorption of carbohydrate .
acarbose , taken in this first bite of food. Suitable for people with high blood sugar after meals.
6. Intestinal entropin promotes insulin secretion after the gastrointestinal intake of food.
Glucagon-like peptides: liraglutide , exenatide , subcutaneous injection, suitable for type 2 obesity and insulin resistance; dipeptidyl peptidase inhibitors: sitagliptin, sagliptin , oral administration.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-